Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 ROC curve analysis of the clinical application value of the established diagnostic model based on the differentially expressed GTs for bladder cancer

From: ɑ1,3-mannosyltransferase promotes the malignant progression of bladder cancer through activating TNF signaling pathway

Data set

Factors

AUC

Sensitivity (%)

Specificity (%)

Training test–TCGA–BLCA

ALG3

0.939

84.1

88.9

POMT2

0.764

63.2

76.6

UGCG

0.799

85.9

63.1

XXYLT1

0.787

64.2

80.1

COLGALT1

0.780

62.6

81.0

A4GALT

0.758

57.7

89.8

combined

0.966

88.5

92.6

Testing test–GSE188715

combined

0.960

92.8

87.3

Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us